IPN Ipsen S.A.
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience in North America, Europe, and internationally. It engages in the development of Somatuline for neuroendocrine tumors and acromegaly indications; and Dysport for motor muscular disorders and medical aesthetics indications; and Decapeptyl for advanced metastatic prostate cancer, uterine fibroids, central precocious puberty, endometriosis, female infertility, and early-stage breast cancer in combination with hormone therapy. The company also develops Cabometyx for renal cell carcinoma, second line hepatocellular carcinoma, differentiated thyroid cancer, and neuroendocrine tumors; Onivyde for second-line metastatic pancreatic cancer; and Bylvay for the treatment of progressive familial intrahepatic cholestasis and cholestatic pruritus in patients with both PFIC and Alagille syndrome. In addition, it is involved in the development of Iqirvo for the second line treatment for primary biliary cholangitis; Sohonos for the treatment to reduce new, abnormal bone formation in soft and connective tissues, in people living with ultra-rare bone disease, and fibrodysplasia ossificans progressiva; and IPN60340 in Phase I/II clinical trial for first line acute myeloid leukemia indications. Further, the company develops Tazverik + rituximab and lenalidomide in Phase III clinical trials for second line follicular lymphoma indications; Tovorafenib in Phase III clinical trials for first line pediatric low-grade gliomas indications; and IPN01194, IPN01195, IPN60300, and IPN01203 in Phase I for solid tumors indications; and IPN10200 in Phase II clinical trials for aesthetic and therapeutic indications. Ipsen S.A. was founded in 1929 and is headquartered in Paris, France.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Ipsen (EPA: IPN)
›
Ipsen (EPA: IPN) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 5,535 employees.
The shares were at 162.40 EUR on 19 November 2026, up 27.8% over 52 weeks. Its 52-week range is 115.60 EUR to 174.00 EUR: the price is 6.7% below the high and 40.5% above the low.
At a market capitalisation of 13.39B EUR, it trades at 26.3 times trailing earnings and 11.2 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, so IPN is valued in line with them. It pays a dividend yielding 0.98% (it pays out 26% of its earnings), against a median of 2.01% among the dividend payers in that peer group.
Ipsen reports return on equity of 10.2%, an operating margin of 27.4% and revenue up 18.7% year over year.
It holds more cash than debt, a net cash position of 1.01B EUR. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 13 analysts cover the stock, with an average rating of Hold; their mean price target of 162.23 EUR is 0.1% below the current price. The next earnings report is expected on 11 February 2027.